Simple Summary Aggressive metastatic disease is rare in papillary thyroid carcinoma (PTC),
a neoplasia that usually carries an excellent prognosis. BRAF, RAS, and TERT promoter …

A unique prognostic role of the genetic duet of BRAF V600E and TERT promoter mutations
in papillary thyroid cancer (PTC) has been recently established, but the role of RAS mutation …

Introduction The use of molecular markers, especially BRAF and TERT promoter mutations,
for risk stratification in papillary thyroid carcinoma (PTC) is subject to continuing debate. In …

The prognostic role of molecular markers in papillary thyroid carcinoma (PTC) is a matter of
ongoing debate. The aim of our study is to investigate the impact of RAS, BRAF, TERT …

Background: Telomerase reverse transcriptase promoter (TERT p) mutations are related to a
worse prognosis in various malignancies, including papillary thyroid carcinoma (PTC). Since …

Several previous studies have shown that mutations in B‑Raf proto‑oncogene (BRAF) and
telomerase reverse transcriptase (TERT) can be used for the diagnosis and prognosis of …

The role of telomerase reverse transcriptase (TERT) gene promoter mutations in the
aggressiveness of papillary thyroid cancer (PTC) remains to be further investigated. Here we …

Importance BRAF V600E andTERTpromoter mutations can coexist in papillary thyroid
cancer (PTC). This genetic duet was indicated to be involved in the aggressiveness of PTC …

Context: Papillary thyroid carcinoma (PTC) carrying the BRAF mutation has been reported to
be associated with high recurrence and potentially increased mortality. PTC carrying the …

BRAFV600E mutation is highly prevalent in patients with papillary thyroid carcinoma (PTC),
and TERT promoter (TERTp) mutation is strongly associated with cancer‐related mortality …